Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vaxcyte, Inc. Director's Dealing 2024

Jan 25, 2024

31100_dirs_2024-01-25_0e478e18-a6b5-4c2c-82b0-da83cc7547af.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-01-23

Reporting Person: PICKERING GRANT (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-01-23 Common Stock M 3000 $0.04 Acquired 378814 Direct
2024-01-23 Common Stock M 12000 $1.79 Acquired 390814 Direct
2024-01-23 Common Stock S 2938 $63.215 Disposed 387876 Direct
2024-01-23 Common Stock S 10023 $63.95 Disposed 377853 Direct
2024-01-23 Common Stock S 2039 $64.78 Disposed 375814 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-01-23 Stock Option (Right to Buy) $0.04 M 3000 Disposed 2025-04-23 Common Stock (3000) Direct
2024-01-23 Stock Option (Right to Buy) $1.79 M 12000 Disposed 2027-05-17 Common Stock (12000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 151286 Indirect
Common Stock 151286 Indirect

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $62.625 to $63.61. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $63.66 to $64.625. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $64.70 to $64.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: Shares are held directly by a trust for the benefit of the Reporting Person's daughter.

F6: Shares are held directly by a trust for the benefit of the Reporting Person's son.

F7: Stock Option is fully vested and exercisable.